Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Ponesimod
Cat. No.:
OB0225LY-0082
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
Ponesimod is a selective S1P modulator. It reduces inflammation in the nervous system by regulating the movement and activity of T cells.
Synonym:
ACT-128800; 854107-55-4; (2Z,5Z)-5-(3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one; (5Z)-5-[[3-Chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one; (Z)-5-((Z)-3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one
CAS No.:
854107-55-4
Compound CID:
11363176
Formula:
C23H25ClN2O4S
Formula Weight:
460.97
Specification
Relative Density:
1.30 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Ponesimod can be used for autoimmune disease research.
Library Information
Targets:
S1P receptor; LPL receptor
Receptors:
LPL; S1P1
Pathways:
GPCR/G protein
Plate Number:
AOCL-2
Plate Location:
a5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 119.31 mM
Ethanol Max Solubility:
92 mg/mL; 199.58 mM
